Hemophilia A2030 Market
DelveInsight's "Hemophilia A Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Hemophilia A, historical and forecasted epidemiology as well as the Hemophilia A market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Hemophilia A market report provides current treatment practices, emerging drugs, Hemophilia A market share of the individual therapies, current and forecasted Hemophilia A market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Hemophilia A treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2017-2030
Hemophilia A Disease Understanding and Treatment Algorithm
Hemophilia A is an X chromosome-linked genetic disorder caused by the mutations in the genes for factor VIII (FVIII). This clotting factor is a part of the intrinsic pathway of blood coagula tion. Without enough factor VIII, the blood cannot clot properly to control bleeding. It is mainly a defect in the gene on chromosome X, females have two copies of the X chromosome. So, if the factor VIII gene on one chromosome does not work, the gene on the other chromosome can do the job of making enough factor VIII. On the other hand, males have only one X chromosome; if the factor VIII gene is missing on the male X chromosome, he will have hemophilia A that is why the most people with Hemophilia A are male.
The symptoms of Hemophilia A can vary greatly from one person to another, it ranges from mild to moderate to severe. The age of onset and frequency of bleeding episodes depend upon the amount of factor VIII protein and overall clotting ability of the blood. In most individuals, regardless of severity, bleeding episodes tend to be more frequent in childhood and adolescence than in adulthood.
Additionally, the diagnosis of Hemophilia A depends on the identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation, and a variety of specialized laboratory tests. The identification of a hemizygous F8 pathogenic variant on molecular genetic testing in a male proband confirms the diagnosis.
The treatment of Hemophilia A is mainly focused on the prophylaxis as there is no cure for hemophilia A. Treatment consists of replacing the missing clotting protein (factor VIII) and preventing the complications associated with the disorder. Replacement of this protein may be obtained through recombinant factor VIII, which is artificially created in a lab. Several recombinant forms of factor VII are also approved for the treatment of hemophilia A. In some cases, subjects with hemophilia A may develop ‘inhibitors’ against the replacement factor VIII. Inhibitors are antibodies, which are specialized proteins created by the body’s immune system to combat foreign or invading substances such as toxins or bacteria. The immune system may recognize replacement factor VIII as ‘foreign’ and create these antibodies (inhibitors), which target and destroy the replacement factor. For inhibitors treatment is mainly dependent on bypassing agents and immne tolerance therapy (ITI).
Hemophilia A Epidemiology
The Hemophilia A epidemiology division provide insights about historical and current Hemophilia A patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
DelveInsight’s analysts have assessed that the total prevalent population of Hemophilia A in the 7MM was 42,458 in 2017. In addition to this, it was accessed that the total diagnosed and treated prevalent population of Hemophilia A in the 7MM was assessed to be 38,212 in 2017.
Country Wise- Hemophilia A Epidemiology
The epidemiology segment also provides the Hemophilia A epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Hemophilia A Drug Chapters
Hemophilia A can be characterized by immediate or delayed bleeding or prolonged oozing after injuries, tooth extractions, or surgery or renewed bleeding after initial bleeding has stopped. Prolonged or delayed bleeding or wound hematoma formation after surgery is common. After circumcision, males with hemophilia A of any severity may have prolonged oozing, or they may heal normally without treatment. In severe hemophilia A, spontaneous joint bleeding is the most frequent symptom.
The treatment of hemophilia A is based upon the severity of disease if the disease is mild and moderate then on-demand (episodic) treatment will be given, and if the disease is severe, then continuous prophylaxis treatment is given. Some individuals with severe hemophilia A may receive periodic factor VIII infusions at regular intervals to prevent bleeding episodes and associated complications, such as joint damage. This is referred to as prophylactic therapy.
The treatment landscape of Hemophilia A comprises of recombinant or plasma derived Factor VIII (long and short acting) as well as antibody for non-inhibitors patients and for inhibitors Hemophilia A patients the treatment is mainly comprises of by passing agents and ITI.
The US Food and Drug Administration (FDA) has approved several recombinant forms of factor VIII for the treatment of hemophilia A, including HelixateFS (CSL Behring); Recombinate (Baxter); Kogenate FS (Bayer HealthCare); Advate (Baxter); ReFacto (Pfizer); Eloctate (Biogen-Idec), and Xyntha (Pfizer). Human plasma-derived preparations include Monarc-M (Baxter), Monoclate-P (CSL Behring), Hemofil M (Baxter), Koate-DVI (Kedrion), Nuwiq (Octapharma), Adynovate (Baxalta), and Jivi (Bayer). Individuals with mild or moderate hemophilia A may be treated with replacement therapy as needed (i.e., to treat specific bleeding episodes). This is referred to as ‘on-demand’ therapy.
Another breakthrough treatment for both Inhibitors and non-inhibitors patients is Hemlibra (Roche) which was approved by US FDA in 2017. It is a bispecific monoclonal antibody for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A.
Hemophilia A Market Outlook
The market size of Hemophilia A in seven major markets (7MM) is estimated to be USD 6,266 million in 2017. The United States accounts for the highest market size of Hemophilia A, i.e., USD 3,178 million, in comparison to the other major markets i.e., EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Among the EU5 countries, the United Kingdom had the highest market size in 2017, while Spain had the lowest market size of Hemophilia A in 2017.
This section includes a glimpse of the Hemophilia A market in 7MM.
The United States Market Outlook
This section provides the total Hemophilia A market size and market size by therapies in the United States.
EU-5 Countries: Market Outlook
The total Hemophilia A market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Market Outlook
The total Hemophilia A market size and market size by therapies in Japan is also mentioned.
Hemophilia A Drugs Uptake
With the launch of emerging therapies like Valoctocogene Roxaparvovec (BMN 270, a product of Biomarin Pharmaceutical), which is a gene therapy based on the use of adeno-associated virus (AAV) vectors, Concizumab (NN7415, a product of Novo Nordisk), Fitusiran (Sanofi Genzyme/ Alnylam Pharmaceuticals), BIVV001 (Sanofi), Marstacimab (Pfizer), SPK-8011 (Spark Therapeutics) and others, the market of Hemophilia A is anticipated to change during the forecast period (2019–2030).
Products that are anticipated to be launched during the forecast period are in late clinical stages of development, while others are in ongoing late clinical development stages. Some of the above-mentioned drug candidates have shown very promising results and it has been anticipated by DelveInsight’s analysts that completion of clinical development and launch of these products in the market, might increase the market share of these companies, and besides this, patients of Hemophilia A will have better management practices.
According to our assessment, potential emerging candidates shall launch in the upcoming years of the forecast period [2019–2030], and with their anticipated launch, the market size of Hemophilia A will also experience significant growth.
Hemophilia A Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Hemophilia A key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Hemophilia A emerging therapies.
Reimbursement Scenario in Hemophilia A
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
To keep up with current market trends, we take KOLs and SME's opinion working in Hemophilia A domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Hemophilia A market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Hemophilia A Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Hemophilia A, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Hemophilia A epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Hemophilia A are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Hemophilia A market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hemophilia A market
- In the coming years, Hemophilia A market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Hemophilia A R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Hemophilia A. Launch of emerging therapies will significantly impact the Hemophilia A market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Hemophilia A
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Hemophilia A Report Insights
- Patient Population
- Therapeutic Approaches
- Hemophilia A Pipeline Analysis
- Hemophilia A Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Hemophilia A Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Hemophilia A Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Hemophilia A Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- What was the Hemophilia A market share (%) distribution in 2017 and how it would look like in 2030?
- What would be the Hemophilia A total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest Hemophilia A market size during the forecast period (2017-2030)?
- At what CAGR, the Hemophilia A market is expected to grow in 7MM during the forecast period (2017-2030)?
- What would be the Hemophilia A market outlook across the 7MM during the forecast period (2017-2030)?
- What would be the Hemophilia A market growth till 2030, and what will be the resultant market Size in the year 2030?
- How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
- What is the disease risk, burden and unmet needs of the Hemophilia A?
- What is the historical Hemophilia A patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Hemophilia A in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Hemophilia A?
- Out of all 7MM countries, which country would have the highest prevalent population of Hemophilia A during the forecast period (2017-2030)?
- At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the Hemophilia A treatment, along with the approved therapy?
- What are the current treatment guidelines for the treatment of Hemophilia A in the USA, Europe, and Japan?
- What are the Hemophilia A marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Hemophilia A?
- How many therapies are developed by each company for Hemophilia A treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Hemophilia A treatment?
- What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Hemophilia A therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Hemophilia A and their status?
- What are the key designations that have been granted for the emerging therapies for Hemophilia A?
- What are the global historical and forecasted market of Hemophilia A?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Hemophilia A market
- To understand the future market competition in the Hemophilia A market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Hemophilia A in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Hemophilia A market
- To understand the future market competition in the Hemophilia A market
What is Hemophilia A?
Hemophilia A is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor VIII
What was the market size of Hemophilia A in 2017?
The market size for Hemophilia A was found to be USD 6,266 Million in 2017
What are the Hemophilia A market drivers?
Popularity of Gene Therapy, Development of Novel Treatments with extended half-life, and Increased Focus on Prophylactic Treatment are the Hemophilia A market drivers
What are the Hemophilia A market barriers?
High Cost of Treatment, Inconvenience and Scheduling Barriers, and Lack of Skilled Healthcare Professionals are the Hemophilia A market barriers
Which companies are developing drugs for Hemophilia A?
Biomarin Pharmaceutical, Novo Nordisk, Sanofi, Pfizer, Catalyst Biosciences, OPKO Biologics, Spark Therapeutics, Sangamo therapeutics are developing drugs for Hemophilia A